| P3 amplitude |
phenotype |
12 |
11 |
P3, P3 amplitude, P3 amplitude reduction, P3 deficit, P3 endophenotype, P3 reduction, P3 wave amplitude, amplitude of the P3 wave, auditory P3 peak amplitude, low amplitude of P3 components, parietal P3 amplitude, psychophysiological marker of AD risk, reduced P3 amplitude, visual P3 peak amplitude |
| P3b amplitude |
phenotype |
9 |
7 |
P3b, P3b amplitudes, amplitude of P3b |
| P3b component |
phenotype |
2 |
1 |
P3b |
| P3 component |
phenotype |
10 |
8 |
P3, P3 peak, P3 peaks, P3 related phenotypes, P300, P300 response |
| P3 latency |
phenotype |
4 |
3 |
P3 latencies, P3 latency |
| PAC |
phenotype |
2 |
— |
phase-amplitude coupling |
| pack-years |
phenotype |
4 |
3 |
average lifetime cigarette use, cigarette pack-years, lifetime cigarette exposure, lifetime cigarette use, pack years, smoking duration |
| PAH |
gene |
2 |
2 |
PAH gene, phenylalanine hydroxylase, phenylalanine hydroxylase gene |
| pain |
phenotype |
10 |
8 |
moderate to severe pain, pain patients, pain perception, pain phenotypes |
| pain perception |
phenotype |
4 |
2 |
perception of pain |
| pain sensitivity |
phenotype |
4 |
3 |
global measures of pain sensitivity, higher pain sensitivity, pain sensitivity score, pain-sensitivity phenotypes |
| pair bonding |
phenotype |
6 |
5 |
human pair bonding, measures indicative of pair-bonding |
| palmitic acid |
drug |
2 |
— |
14C-P, C16:0, [U-14C]palmitic acid, palmitic acid |
| Palpitations |
phenotype |
3 |
1 |
|
| pancreatic cancer |
phenotype |
9 |
1 |
pancreatic |
| panic disorder |
phenotype |
36 |
22 |
DSM‑IV panic disorder, ICD-10 F41.0, ICD-9 3000B, ICD-9 3002B, PA, PD, first panic attack, panic, panic attacks, panic disorder, panic disorder with or without agoraphobia, primary panic disorder |
| Papain |
drug |
6 |
3 |
|
| paraffin |
drug |
4 |
2 |
PFPE |
| paraformaldehyde |
drug |
35 |
13 |
32% paraformaldehyde, 4% PFA, 4% paraformaldehyde, Electron Microscopy Sciences #15714, PFA, paraformaldahyde |
| paranoia |
phenotype |
5 |
2 |
paranoid |
